Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 4/2016

01-04-2016 | Original Contributions

A Systematic Review and Meta-analysis of the Effect of Gastric Bypass Surgery on Plasma Lipid Levels

Authors: Kirstin A. Carswell, Ajay P. Belgaumkar, Stephanie A. Amiel, Ameet G. Patel

Published in: Obesity Surgery | Issue 4/2016

Login to get access

Abstract

Background

Obesity-related dyslipidaemia comprises hypercholesterolaemia, hypertriglyceridaemia, low HDL-cholesterol and normal to raised LDL-cholesterol levels. 40 % of morbidly obese surgical patients have dyslipidaemia. Roux-en-Y gastric bypass (RYGB) surgery has many beneficial metabolic effects, but the full impact on plasma lipids has not been clearly defined.

Methods

A systematic review of electronic databases (Ovid; Medline; PubMed; Embase) between 1960 and March 2012 was performed using search terms including the following: obesity surgery, bariatric surgery, gastric bypass, cholesterol, lipids, triglycerides and non-esterified fatty acids. A total of 2442 manuscripts were screened. Papers with paired plasma lipid levels around RYGB surgery were included. Exclusions included the following: editorials, dual publications, n < 10, resulting in 75 papers of relevance. A meta-analysis was performed of the effect of RYGB surgery upon plasma lipids at different time points up to 4 years following surgery, using a random effects model.

Results

Paired data were available for 7815 subjects around RYGB surgery for morbid obesity with a baseline BMI 48 kg/m2 (n = 2331). There was a reduction in plasma total cholesterol and LDL-C from 1 month up to 4 years post-RYGB (p < 0.00001, p < 0.00001). Following RYGB, HDL-C increased from 1 year onwards (p < 0.00001), and triglyceride levels were reduced postoperatively from 3 months up to 4 years (p < 0.00001). NEFA levels were increased at 1 month postoperatively (p = 0.003), but from 3 months onwards did not differ from preoperative levels (p = 0.07).

Conclusions

RYGB surgery reverses the dyslipidaemia of obesity. These findings support the use of RYGB in the management of high cardiovascular risk lipid profiles in morbid obesity.
Literature
1.
Mason EE, Ito C. Gastric bypass in obesity. Surg Clin N Am. 1967;47:1345.PubMed
2.
Griffen Jr WO, Young VL, Stevenson CC. A prospective comparison of gastric and jejuno-ileal bypass procedures for morbid obesity. Ann Surg. 1977;186:500.PubMedPubMedCentralCrossRef
3.
Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operative proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;22:339–52.CrossRef
4.
Maggard MA, Sugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142:547–59.PubMedCrossRef
5.
Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. NEJM. 2004;351:2683–93.PubMedCrossRef
6.
Buchwald H, Estok R, Fahrback K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56. e5.PubMedCrossRef
7.
Lee WJ, Chong K, Chen CY, et al. Diabetes remission and insulin secretion after gastric bypass in patients with BMI < 35 kg/m2. Obes Surg. 2011;21:889–95.PubMedCrossRef
8.
Meijer RI, van Wagensveld BA, Siegert CE, et al. Bariatric surgery as a novel treatment for type 2 diabetes mellitus: a systematic review. Arch Surg. 2011;146:744–50.PubMedCrossRef
9.
Ferchak CV, Meneghini LF. Obesity, bariatric surgery and type 2 diabetes—a systematic review. Diabetes Metab Res Rev. 2004;20:438–45.PubMedCrossRef
10.
11.
Howard BV. Obesity and dyslipidaemia. Endocrinol Metab Clin N Am. 2003;32:855–67.CrossRef
12.
Keys A, Menotti A, Aravanis C, et al. The seven countries study: 2,289 deaths in 15 years. Prev Med. 1984;13:141–54.PubMedCrossRef
13.
Williams KJ, Tabas I. The response to retention hypothesis of early atherogenesis. Arterioscler Thromb. 1995;15:551–61.CrossRef
14.
Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22:1640–54.
15.
Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–80.PubMedCrossRef
16.
Hensen LO, Thayssen P, Pedersen KE, et al. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation. 2004;110:265–70.CrossRef
17.
Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation. 2004;110:1061–8.PubMedCrossRef
18.
Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment. Prospective meta-analysis of data from 90, 056 participants in randomized trials of statins. Lancet. 2005;366:1267–78.PubMedCrossRef
19.
Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499–508.PubMedCrossRef
20.
Thomas CB, Cohen BH. The familial occurrence of hypertension and coronary artery disease, with observations concerning obesity and diabetes. Ann Intern Med. 1955;42:90–127.PubMedCrossRef
21.
The Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Peri-operative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361:445–54.CrossRef
22.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. BMJ. 2009;3:e123–30.
23.
Buffington CK, Cowan GSM, Hughes TA, et al. Significant changes in the lipid-lipoprotein status of premenopausal morbidly obese females following gastric bypass surgery. Obes Surg. 1994;4:328–35.PubMedCrossRef
24.
Cowan Jr GS, Buffington CK. Significant changes in blood pressure, glucose, and lipids with gastric bypass surgery. World J Surg. 1998;22:987–92.PubMedCrossRef
25.
Buchwald H, Estok Z, Fahrback K, et al. Trends in mortality in bariatric surgery. Surgery. 2007;142:621–35.PubMedCrossRef
26.
Langin D. Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol Res. 2006;53:482–4919.PubMedCrossRef
27.
Dixon JB, O’Brien P. A disparity between conventional lipid and insulin resistance markers at body mass index levels greater than 34 kg/m2. Int J Obes Metab Dis. 2001;25:793–7.CrossRef
28.
Brolin RE, Kenler HA, Wilson AC, et al. Serum lipids after gastric bypass surgery for morbid obesity. Int J Obes. 1990;14:939–50.PubMed
29.
Wolf AM, Beisiegel U, Kortner B, et al. Does gastric restriction surgery reduce the risks of metabolic diseases? Obes Surg. 1998;8:9–13.PubMedCrossRef
30.
Kelly TM, Jones SB. Changes in serum lipids after gastric bypass surgery. Lack of a relationship to weight loss. Int J Obes. 1986;10:443–52.PubMed
31.
Gleysteen JJ, Barboriak JJ. Improvement in heart disease risk factors after gastric bypass. Arch Surg. 1983;118:681–3.PubMedCrossRef
32.
Gonen B, Halverson JD, Schonfeld G. Lipoprotein levels in morbidly obese patients with massive, surgically induced weight loss. Metabolism. 1983;32:492–6.PubMedCrossRef
33.
Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946–55.PubMedCrossRef
34.
Christou NV, Sampalis JS, Liberman M, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg. 2004;240:416–24.PubMedPubMedCentralCrossRef
35.
Brown EK, Settle EA, Van Rij AM. Food intake patterns of gastric bypass patients. J Am Diet Assoc. 1982;80:437–43.PubMed
36.
Kenler HA, Brolin RE, Cody RP. Changes in eating behaviour after horizontal gastroplasty and Roux-en-Y gastric bypass. Am J Clin Nutr. 1990;52:87–92.PubMed
37.
Kruseman M, Leimgruber A, Zumbach F, et al. Dietary, weight, and psychological changes among patients with obesity, 8 years after gastric bypass. J Am Diet Assoc. 2010;110:527–34.PubMedCrossRef
38.
le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246:780–5.PubMedCrossRef
39.
Neary NM, Small CJ, Druce MR, et al. Peptide YY 3–36 and glucagon-like peptide-1 7–36 inhibit food intake additively. Endocrinology. 2005;146:5120–7.PubMedCrossRef
40.
Borg CM, le Roux CW, Ghatei MA, et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2006;93:210–5.PubMedCrossRef
41.
Thirlby RC, Bahiraei F, Randall J, et al. Effect of Roux-en-Y gastric bypass on satiety and food likes: the role of genetics. J Gastrointest Surg. 2006;10:270–7.PubMedCrossRef
42.
Olbers T, Bjorkman S, Lindroos A, et al. Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial. Ann Surg. 2006;244:715–22.PubMedPubMedCentralCrossRef
43.
Odstrcil EA, Martinez JG, Santa Ana CA, et al. The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr. 2010;92:704–13.PubMedCrossRef
44.
Coughlin K, Bell RM, Bivins BA, et al. Preoperative and postoperative assessment of nutrient intakes in patients who have undergone gastric bypass surgery. Arch Surg. 1983;118:813–6.PubMedCrossRef
45.
Mathews DH, Lawrence Jr W, Poppell JW, et al. Change in effective circulating volume during experimental dumping syndrome. Surgery. 1960;48:185–94.PubMed
46.
Dapri G, Cadiere GB, Himpens J. Laparoscopic reconversion of Roux-en-Y gastric bypass to original anatomy: technique and preliminary outcome. Obes Surg. 2011;21:1289–95.PubMedCrossRef
47.
Dietal M. The change in the dumping syndrome concept. Obes Surg. 2008;18:1622–4.CrossRef
48.
Brolin RL, Robertson LB, Kenler HA, et al. Weight loss and dietary intake after vertical banded gastroplasty and Roux-en-Y gastric bypass. Ann Surg. 1994;220:782–90.PubMedPubMedCentralCrossRef
49.
Ito C, Mason EE. Gastric bypass and pancreatic secretion. Surgery. 1971;69:526–32.PubMed
50.
Pihlajamaki J, Gronlund S, Simonen M, et al. Cholesterol absorption decreases after Roux-en-Y gastric bypass but not after gastric banding. Metabolism. 2010;59:866–72.PubMedCrossRef
51.
Carswell KA, Vincent RP, Belgaumkar AP, et al. The effect of bariatric surgery on intestinal absorption and transit time. Obes Surg. 2014;24(5):796–805.PubMedCrossRef
52.
Kumar R, Lieske JC, Collazo-Clavell ML, et al. Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. Surgery. 2011;149:654–61.PubMedPubMedCentralCrossRef
53.
Gonlachanvit S, Coleski R, Owyang C, et al. Inhibitory actions of a high fibre diet on intestinal gas transit in healthy volunteers. Gut. 2004;53:1577–82.PubMedPubMedCentralCrossRef
54.
Flint A, Raben A, Ersboll AK, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes. 2001;25:781–92.CrossRef
55.
Werling M, Vincent RP, Cross GF, et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol. 2013;48:1257–64.PubMedCrossRef
56.
Ponsky TA, Brody F, Pucci E. Alterations in gastrointestinal physiology after Roux-en-Y gastric bypass. Am J Coll Surg. 2005;201:125–30.CrossRef
57.
Kohli R, Bradley D, Setchell KD, et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab. 2013;98:708–12.CrossRef
58.
Simonen M, Dali-Youcef N, Kaminska D, et al. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass. Obes Surg. 2012;22:1473–80.PubMedPubMedCentralCrossRef
59.
Patti ME, Houten SM, Bianco AC, et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity. 2009;17:1671–7.PubMedPubMedCentralCrossRef
60.
Nakatani H, Kasama K, Oshiro T, et al. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism. 2009;58:1400–7.PubMedCrossRef
61.
Pournaras DJ, Glicksman C, Vincent RP, et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153:3613–9.PubMedPubMedCentralCrossRef
62.
63.
Wang PY, Caspi L, Lam CK, et al. Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature. 2008;452:1012–6.PubMedCrossRef
64.
Kong LC, Tap J, Aron-Wisnewsky J, et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr. 2013;98:16–24.PubMedCrossRef
65.
Knop FK. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? Am J Physiol Endocrinol Metab. 2010;299:10–3.CrossRef
66.
67.
Cani PD, Osto M, Geurts L, et al. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;3:279–88.PubMedPubMedCentralCrossRef
68.
Miettinen TA, Gylling H. Cholesterol absorption efficiency and sterol metabolism in obesity. Atherosclerosis. 2000;153:241–8.PubMedCrossRef
69.
Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–61.PubMedPubMedCentralCrossRef
70.
Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113–22.PubMedCrossRef
71.
Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol. 2009;54:1787–94.PubMedCrossRef
72.
Miettinen TA. Detection of changes in human cholesterol metabolism. Ann Clin Res. 1970;2:1–21.
73.
La Rosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340–6.CrossRef
74.
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.PubMedCrossRef
75.
Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.CrossRef
76.
ALLHAT Officers and Coordinators for the ALLHAT collaborative research Group. The antihypertensive and lipid-lowering treatment to prevent heart attach trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007.CrossRef
77.
Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.PubMedCrossRef
78.
AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.CrossRef
79.
Giorgino F, Laviola L, Eriksson JQ. Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies. Acta Physiol Scand. 2005;183:13–30.PubMedCrossRef
80.
Carpentier AC, Frisch F, Brassard P, et al. Mechanism of insulin-stimulated clearance of plasma non-esterified fatty acids in humans. Am J Physiol Endocrinol Metab. 2007;292:E693–701.PubMedCrossRef
81.
Miles JM, Wooldridge D, Greliner WJ, et al. Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects. Diabetes. 2003;52:675–81.PubMedCrossRef
82.
Brassard P, Frisch F, Lavoie F, et al. Impaired plasma non-esterified fatty acid tolerance is an early defect in the natural history of type 2 diabetes. J Clin Endocrinol Metab. 2008;93:837–44.PubMedPubMedCentralCrossRef
83.
Yki-Jarvinen II. Ectopic fat accumulation: an important cause of insulin resistance in humans. J R Soc Med. 2002;95 Suppl 42:39–45.PubMedPubMedCentral
84.
Villanueva-Penacarrillo ML, Marques L, Gonzalez N, et al. Effects of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res. 2001;33:73–7.PubMedCrossRef
85.
Sancho V, Trigo MV, Martin-Duce A, et al. Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects. Int J Mol Med. 2006;17:1133–7.PubMed
86.
Valet P, Berlan M, Beauville M, et al. Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein. J Clin Invest. 1990;85:291–5.PubMedPubMedCentralCrossRef
87.
Getty-Kaushik L, Song DH, Boylan MO, et al. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and re-esterification. Obesity. 2006;14:1124–31.PubMedCrossRef
88.
Lafontan M, Langin D. Lipolysis and lipid mobilisation in human adipose tissue. Prog Lipid Res. 2009;48:275–97.PubMedCrossRef
89.
Singer P, Godicke W, Voigt S, et al. Postprandial hyperinsulinaemia in patients with mild essential hypertension. Hypertension. 1985;7:182–6.PubMedCrossRef
90.
Reaven GM, Ilollenbeck C, Jeng C-Y, et al. Measurement of plasma glucose, free fatty acid, lactate and insulin for 24 h in patients with NIDDM. Diabetes. 1988;37:1020–4.PubMedCrossRef
91.
Ruge T, Hodson L, Cheeseman J, et al. Fasted to fed trafficking of fatty acids in human adipose tissue reveals a novel regulatory step for enhanced fat storage. J Clin Endocrinol Metab. 2009;94:1781–8.PubMedCrossRef
92.
Widjaja A, Morris RJ, Levy LC, et al. Within- and between-subject variation in commonly measured anthropometric and biochemical variables. Clin Chem. 1999;45:561–6.PubMed
93.
Magkos F, Patterson BW, Mittendorfer B. Reproducibility of stable isotope-labeled tracer measures of VLDL-triglyceride and VLDL-apolipoprotein B-100 kinetics. J Lipid Res. 2007;48:1204–11.PubMedCrossRef
94.
Sidhu D, Naugler C. Fasting time and lipid levels in a community-based population. Arch Intern Med. 2012;172:1707–10.PubMedCrossRef
95.
Campose H, Khoo C, Sacks FM. Diurnal and acute pattern of postprandial apolipoprotein B-48 in VLDL, IDL and LDL from normolipidemic human. Atherosclerosis. 2005;181:345–51.CrossRef
96.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–421.
97.
De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis. 2004;173:381–91.PubMedCrossRef
98.
Bansal S, Buring JE, Rifai N, et al. Fasting compared with non-fasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309–16.PubMedCrossRef
99.
Nordestgaard BG, Benn M, Scnohr P, et al. Non-fasting triglycerides and risk of myocardial infarction, ischemic heart disease and death in men and women. JAMA. 2007;298:299–308.PubMedCrossRef
100.
Durstine JL, Grandjean PW, Cox CA, et al. Lipids, lipoproteins, and exercise. J Cardpulm Rehabil. 2002;22:385–98.CrossRef
101.
Tamboli RA, Hossain HA, Marks PA, et al. Body composition and energy metabolism following Roux-en-Y gastric bypass surgery. Obesity. 2010;18:1718–24.PubMedPubMedCentralCrossRef
102.
Hatoum IJ, Stein HK, Merrifield BF, et al. Capacity for physical activity predicts weight loss after Roux-en-Y gastric bypass. Obesity. 2008;507:1–8.
103.
Welch G, Wesolowski C, Piepul B, et al. Physical activity predicts weight loss following gastric bypass surgery: findings from a support group survey. Obes Surg. 2008;18:517–24.PubMedCrossRef
104.
Skottheim IB, Stormark K, Christensen H, et al. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin Pharmacol Ther. 2009;86:311–8.PubMedCrossRef
105.
Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11:1–160.
Metadata
Title
A Systematic Review and Meta-analysis of the Effect of Gastric Bypass Surgery on Plasma Lipid Levels
Authors
Kirstin A. Carswell
Ajay P. Belgaumkar
Stephanie A. Amiel
Ameet G. Patel
Publication date
01-04-2016
Publisher
Springer US
Published in
Obesity Surgery / Issue 4/2016
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-015-1829-x

Other articles of this Issue 4/2016

Obesity Surgery 4/2016 Go to the issue

Letter to the Editor

Potential Benefits of Prophylactic Cholecystectomy in Patients Undergoing Bariatric Bypass Surgery

Original Contributions

Prevalence of Barrett’s Esophagus in Bariatric Patients Undergoing Sleeve Gastrectomy

Erratum

Erratum to: Adherence to Psychiatric Follow-up Predicts 1-Year BMI Loss in Gastric Bypass Surgery Patients

New Concept

Preliminary Results of the Influence of Duodenojejunal Bypass in a Porcine Model of Streptozotocin-Induced Diabetes Mellitus

Original Contributions

Malnutrition in Bariatric Surgery Candidates: Multiple Micronutrient Deficiencies Prior to Surgery

Other

Endoluminal therapies for Barrett’s esophagus